Clinical Trial Update: The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 trial examines the safety and preliminary efficacy of BRL-201 in relapsed/refractory B-cell non-Hodgkin lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• BRL-201 (BRL-201)

Snippet

Sponsor: Bioray Laboratories | Conditions: Non-hodgkin Lymphoma,B Cell | Phase 1 | Status: RECRUITING